Synergy Pharmaceuticals Inc (NASDAQ:SGYP) recently announced results of its first phase 3 trial of Plecanatide among those patients who are suffering from constipation-accompanied irritable bowel syndrome. The clinical trials of this first round of phase 3 clinical trials turned positive, the company said. In this round, Synergy checked the safety and efficacy of Plecanatide. This is the medication of company that is primarily an orally-administered compound to be taken once a day.

The study results turn positive

The first out of two trial for Phase 3 of this medication was conducted among 1,135 adult patients suffering from irritable bowel syndrome along with constipation. The company explained that in prelim analysis, the 3 mg and 6 mg doses of new tested drug showed the satisfactory significance. The test was conducted among patients considered to be “Overall Responders.”

The side effect as the company says, which turned out to be the most common of all, was diarrhea. About 3.2% patients showed the symptoms of this event when administered with 3 mg dose. The same event occurred in 3.7% of the patients who received 6 mg dose.

There were 4 patients during the trial who also witnessed serious side effects. The withdrawal symptoms occurred in 1.9% patients for 3 mg dose and 1.8% patients for 6 mg dosage.

New treatment, positive outlook and another feather on Synergy’s cap

Company’s CEO & Chairman, Dr. Gary S. Jacob said that Synergy Pharmaceuticals Inc. is happy to see the positivity of these results. It indicated he stated, that Plecanatide is in a strong position and represents a new option for the patients amongst whom the constipation-accompanied irritable bowel syndrome is common.

The company is now planning to check the results of second phase 3 trial with Plecanatide. The positive results are putting the company in a stronger position from where it can also pitch Plecanatide for positive chronic idiopathic constipation (CIC) treatment in front of FDA. The company has already said that the same treatment is put forth USFDA for chronic idiopathic constipation, expecting positive outcome from the administration.

Previous articleMerrimack Pharmaceuticals Inc (NASDAQ:MACK) Succumbs Breast Cancer Drug Trial
Next articleNewcastle Investment Corp. (NYSE:NCT) To Change From Real Estate Investment Trust To C–Corporation
Steve Kanaval: Portfolio Manager/Writer/ Market Analyst Steve began his career in the Trading Pits in Chicago making markets at the Chicago Mercantile Exchange (NYSE:CME) the Chicago Board of Trade and the CBOE in the early 80’s. He ran the Morgan Stanley Derivative Prop Trading for the firm specializing in Index Arbitrage. He continued his career as a Trader/Portfolio Manager for multiple Hedge Funds during the Internet Boom of the 90’s managing large portfolios. Steve is known as an expert in MicroCap Technology Stocks and the emerging Digital Currency markets as a Portfolio Manager for his Family Office. Steve has managed portfolio’s in volatile asset classes for 3 decades as a commodity trader, hedge fund manager and digital currency trader and miner. Steve publishes his views on the asset classes in a public forum and has published more than 10,000 articles simplifying these complex and volatile assets for readers. His work is published on multiple sites including Bloomberg,,, CryptoCurrencyNews as a paid contributor. His work includes research, journalism and archived video on important market volatility related to stocks, digital currency and other volatile misunderstood asset classes. He offers a humorous, unique insight and the related back stories and drivers for readers interested in volatility and emerging market assets. Full disclosure Steve is long 25 digital currencies and sits on the board of multiple public companies involved in digital currencies, and owns shares in these companies from time to time.